Crestor

Drug Status: Marketed Drug

CRESTOR is a member of the statin class; for the treatment of dyslipidaemia. CRESTOR reduces LDL-C (‘bad’ cholesterol) and raises HDL-C (‘good’ cholesterol).CRESTOR was initially developed by the Japanese pharmaceutical company Shionogi and in-licensed to AstraZeneca in April 1998.For rosuvastatin clinical information please visit www.rosuvastatininformation.com

For further information on Crestor and links to other product specific and disease area websites please click here.

Please consult the prescribing information for the country concerned on the approved use of drug.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.